Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles

Area of Science:

• Immunology
• Nanotechnology
• Therapeutic Drug Delivery

Background:

• Targeting molecular interactions within the T-cell synapse is crucial for immunotherapy, aiming to prevent autoimmunity and enhance anti-tumor responses.
• A significant hurdle in this field is achieving therapeutically effective delivery of immune-modulating agents directly into the synapse.

Purpose of the Study:

• To develop and evaluate a novel method for delivering therapeutic compounds into the T-cell synapse.
• To assess the efficacy of nanoparticle-mediated drug delivery for enhancing T-cell function in cancer immunotherapy.

Main Methods:

• Maleimide-functionalized nanoparticles (NPs) were covalently linked to T-cell membrane proteins via free thiol groups.
• The polarized movement of surface-linked NPs towards the immunological synapse (IS) was observed during T-cell/antigen-presenting cell (APC) interactions.
• The dual Shp1/Shp2 inhibitor NSC-87877, loaded onto NPs, was tested in the context of adoptive T-cell therapy for prostate cancer in mice.

Main Results:

• Surface-linked NPs efficiently delivered compounds into the T-cell synapse, rapidly polarizing towards the IS.
• Conjugating NSC-87877-loaded NPs to tumor-specific T cells significantly enhanced T-cell expansion at the tumor site compared to systemic administration.
• This targeted delivery approach led to improved survival rates in mice with advanced prostate cancer.

Conclusions:

• T-cell-linked synthetic NPs serve as effective drug delivery vehicles for targeted delivery into the immunological synapse.
• This nanoparticle-based strategy offers a promising new paradigm for modulating signaling events at the T-cell/APC interface in immunotherapy.
• The findings support the broad applicability of this approach for enhancing therapeutic outcomes in various immune-related conditions and cancers.